Serena Ludovisi
Overview
Explore the profile of Serena Ludovisi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
837
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lombardi A, Butta G, Donnici L, Bozzi G, Oggioni M, Bono P, et al.
Lancet Reg Health Eur
. 2021 Dec;
13:100287.
PMID: 34961855
Background: Vaccines against COVID-19 are a powerful tool to control the current SARS-CoV-2 pandemic. A thorough description of their immunogenicity among people living with HIV (PLWHIV) is necessary. We aimed...
2.
Bozzi G, Lombardi A, Ludovisi S, Muscatello A, Manganaro L, Cattaneo D, et al.
Int J Infect Dis
. 2021 Oct;
113:125-126.
PMID: 34666164
No abstract available.
3.
Colaneri M, Lupi M, Sachs M, Ludovisi S, Di Matteo A, Pagnucco L, et al.
New Microbiol
. 2021 Jun;
44(2):129-134.
PMID: 34151993
The COVID-19 pandemic is posing an unprecedented threat worldwide. One issue that has faltered, though, concerns the underestimated risk to trade all for COVID-19, misdiagnosing other potentially life-threatening diseases. Further...
4.
Fallerini C, Daga S, Mantovani S, Benetti E, Picchiotti N, Francisci D, et al.
Elife
. 2021 Mar;
10.
PMID: 33650967
Background: Recently, loss-of-function variants in TLR7 were identified in two families in which COVID-19 segregates like an X-linked recessive disorder environmentally conditioned by SARS-CoV-2. We investigated whether the two families...
5.
Varchetta S, Mele D, Oliviero B, Mantovani S, Ludovisi S, Cerino A, et al.
Cell Mol Immunol
. 2020 Oct;
18(3):604-612.
PMID: 33060840
The relationship between severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and host immunity is poorly understood. We performed an extensive analysis of immune responses in 32 patients with severe COVID-19, some...
6.
Biscarini S, Colaneri M, Ludovisi S, Seminari E, Pieri T, Valsecchi P, et al.
Nutr Metab Cardiovasc Dis
. 2020 Sep;
30(11):1920-1925.
PMID: 32988724
Background And Aims: Obesity has been suggested as a possible risk factor for a more severe course of COVID-19; however, conclusive evidence is lacking and few studies have investigated the...
7.
Oliviero B, Varchetta S, Mele D, Mantovani S, Cerino A, Perotti C, et al.
Cell Mol Immunol
. 2020 Sep;
17(10):1101-1103.
PMID: 32879471
No abstract available.
8.
Lombardi A, Colaneri M, Vijayagopal K, Sambo M, Legnazzi P, Sacchi P, et al.
Dig Liver Dis
. 2020 Aug;
53(4):456-460.
PMID: 32732070
Background And Aims: Direct acting antiviral agents (DAAs) have revolutionized the landscape of chronic hepatitis C (CHC) enabling treatment of all those infected. It remains to be determined how the...
9.
Colaneri M, Valsecchi P, Perotti L, Ludovisi S, Seminari E, Pieri T, et al.
Liver Int
. 2020 Jul;
40(11):2655-2659.
PMID: 32679617
Liver impairment is frequent in patients with novel coronavirus disease (COVID-19) and direct viral tropism for the liver has been proven. Since several of the currently administered drugs against severe...
10.
Mele D, Oliviero B, Mantovani S, Ludovisi S, Lombardi A, Genco F, et al.
Hepatology
. 2020 Apr;
73(1):79-90.
PMID: 32281670
Background And Aims: Current evidence suggests that dysfunctional natural killer (NK) cell responses during hepatitis C virus (HCV) infection can be restored after viral eradication with direct acting antivirals (DAAs)....